Repurposing the CRISPR-Cas9 system for targeted DNA methylation

Aleksandar Vojta,Paula Dobrinić,Vanja Tadić,Luka Bočkor,Petra Korać,Boris Julg,Marija Klasić,Vlatka Zoldoš

DOI: https://doi.org/10.1093/nar/gkw159

IF: 14.9

2016-03-11

Nucleic Acids Research

Abstract:Epigenetic studies relied so far on correlations between epigenetic marks and gene expression pattern. Technologies developed for epigenome editing now enable direct study of functional relevance of precise epigenetic modifications and gene regulation. The reversible nature of epigenetic modifications, including DNA methylation, has been already exploited in cancer therapy for remodeling the aberrant epigenetic landscape. However, this was achieved non-selectively using epigenetic inhibitors. Epigenetic editing at specific loci represents a novel approach that might selectively and heritably alter gene expression. Here, we developed a CRISPR-Cas9-based tool for specific DNA methylation consisting of deactivated Cas9 (dCas9) nuclease and catalytic domain of the DNA methyltransferase DNMT3A targeted by co-expression of a guide RNA to any 20 bp DNA sequence followed by the NGG trinucleotide. We demonstrated targeted CpG methylation in a ∼35 bp wide region by the fusion protein. We also showed that multiple guide RNAs could target the dCas9-DNMT3A construct to multiple adjacent sites, which enabled methylation of a larger part of the promoter. DNA methylation activity was specific for the targeted region and heritable across mitotic divisions. Finally, we demonstrated that directed DNA methylation of a wider promoter region of the target loci IL6ST and BACH2 decreased their expression.

biochemistry & molecular biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a tool that can specifically target DNA methylation in mammalian cells. Specifically, the author aims to achieve this goal by using the CRISPR - Cas9 system. By fusing the inactivated Cas9 (dCas9) with the catalytic domain of the DNA methyltransferase DNMT3A, DNA methylation modifications can be introduced at specific gene loci.

### Main Problem Analysis

1. **Limitations of Traditional Methods**
- Previous epigenetic research mainly relied on the correlation between epigenetic marks and gene expression patterns.
- Although existing epigenetic editing techniques can study the functional correlation of specific epigenetic modifications, these methods are usually non - selective. For example, inhibitors are used to change the epigenetic state of the entire genome.

2. **Necessity of Targeted DNA Methylation**
- Non - selective epigenetic modifications cannot precisely regulate the expression of specific gene loci.
- Specifically introducing DNA methylation in certain gene promoter regions can more accurately study the functions of these genes and has potential therapeutic applications, such as cancer treatment and regulation of autoimmune diseases.

### Solution

The author proposes a new tool based on the CRISPR - Cas9 system for specific DNA methylation:

- **Construction Idea**: Fuse the inactivated Cas9 (dCas9) with the catalytic domain of the DNA methyltransferase DNMT3A to form the dCas9 - DNMT3A fusion protein.
- **Targeting Mechanism**: The sgRNA guides the dCas9 - DNMT3A complex to specific DNA sequences, thereby introducing DNA methylation at these sites.
- **Verification of Effect**: Experimental results show that this tool can specifically introduce CpG methylation in an area approximately 35 bp wide, and this methylation is heritable.

### Experimental Verification

1. **Dose - Response Experiment**: The optimal amount of dCas9 - DNMT3A plasmid was determined to achieve saturated target activity and minimize non - specific activity.
2. **Multi - sgRNA Experiment**: By simultaneously guiding dCas9 - DNMT3A to adjacent sites with multiple sgRNAs, DNA methylation in a larger area was achieved.
3. **Functional Verification**: It was proved that after introducing DNA methylation in the promoter regions of the IL6ST and BACH2 genes, the expression levels of these genes were significantly reduced.

### Conclusion

This study successfully developed a tool based on the CRISPR - Cas9 system that can introduce DNA methylation modifications at specific gene loci, providing a new method for epigenetic editing and laying the foundation for future research and therapeutic applications.